These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 28498807)

  • 1. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
    Lu WQ; Hu YY; Lin XP; Fan W
    Oncotarget; 2017 Jul; 8(27):44171-44185. PubMed ID: 28498807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
    Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
    PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer.
    Wang X; Zhang H; Yang H; Bai M; Ning T; Deng T; Liu R; Fan Q; Zhu K; Li J; Zhan Y; Ying G; Ba Y
    Mol Oncol; 2020 Mar; 14(3):539-555. PubMed ID: 31901148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gegen Qinlian Decoction reverses oxaliplatin resistance in colorectal cancer by inhibiting YTHDF1-regulated m6A modification of GLS1.
    Lin X; Xu L; Gu M; Shao H; Yao L; Huang X
    Phytomedicine; 2024 Oct; 133():155906. PubMed ID: 39089089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
    Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
    Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer.
    Li Q; Zhang D; Chen X; He L; Li T; Xu X; Li M
    Sci Rep; 2015 Nov; 5():16082. PubMed ID: 26542452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
    Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
    Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of anti-tumor effect and mechanism of GLS1 inhibitor CB-839 in colorectal cancer using a stroma-abundant tumor model.
    Miyamoto R; Takigawa H; Yuge R; Shimizu D; Ariyoshi M; Otani R; Tsuboi A; Tanaka H; Yamashita K; Hiyama Y; Urabe Y; Ishikawa A; Sentani K; Oka S
    Exp Mol Pathol; 2024 Jun; 137():104896. PubMed ID: 38703552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of shRNA-Mediated Silencing of PKM2 Gene on Aerobic Glycolysis, Cell Migration, Cell Invasion, and Apoptosis in Colorectal Cancer Cells.
    Yan XL; Zhang XB; Ao R; Guan L
    J Cell Biochem; 2017 Dec; 118(12):4792-4803. PubMed ID: 28543190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment.
    Zhou Y; Huang Z; Su J; Li J; Zhao S; Wu L; Zhang J; He Y; Zhang G; Tao J; Zhou J; Chen X; Peng C
    Int J Cancer; 2020 Jul; 147(1):139-151. PubMed ID: 31652354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CircAGFG1 absence decreases PKM2 expression to enhance oxaliplatin sensitivity in colorectal cancer in a miR-7-5p-dependent manner.
    Chen J; Wang H; Tang M
    J Chemother; 2024 May; 36(3):208-221. PubMed ID: 37691430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lupeol alters ER stress-signaling pathway by downregulating ABCG2 expression to induce Oxaliplatin-resistant LoVo colorectal cancer cell apoptosis.
    Chen MC; Hsu HH; Chu YY; Cheng SF; Shen CY; Lin YJ; Chen RJ; Viswanadha VP; Lin YM; Huang CY
    Environ Toxicol; 2018 May; 33(5):587-593. PubMed ID: 29436100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer.
    Dong Y; Wang Z; Xie GF; Li C; Zuo WW; Meng G; Xu CP; Li JJ
    Mol Cancer; 2017 Mar; 16(1):71. PubMed ID: 28356150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
    Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
    J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting PKM2 promotes chemosensitivity of breast cancer cells in vitro and in vivo.
    Wang Y; Zhao H; Zhao P; Wang X
    Cancer Biomark; 2021; 32(2):221-230. PubMed ID: 34092620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L-OHP.
    Tang H; Liu YJ; Liu M; Li X
    Anticancer Drugs; 2007 Jul; 18(6):633-9. PubMed ID: 17762391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
    J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptin Inhibits Glycolysis and Regulates Autophagy by Targeting Pyruvate Kinase M2 (PKM2) in Lung Cancer A549 Cells.
    Song G; Shang C; Zhu Y; Xiu Z; Li Y; Yang X; Ge C; Han J; Jin N; Li Y; Li X; Fang J
    Curr Cancer Drug Targets; 2024; 24(4):411-424. PubMed ID: 36284386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer.
    Taniguchi K; Sugito N; Kumazaki M; Shinohara H; Yamada N; Nakagawa Y; Ito Y; Otsuki Y; Uno B; Uchiyama K; Akao Y
    Cancer Lett; 2015 Jul; 363(1):17-27. PubMed ID: 25818238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
    Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
    Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.